

Pharmaceutical Chemicals in Perspective

Bryan G. Reuben

South Bank Polytechnic
London, England

Harold A. Wittcoff

The Chem Systems Group
Tarrytown, New York



A WILEY-INTERSCIENCE PUBLICATION

John Wiley & Sons

NEW YORK / CHICHESTER / BRISBANE / TORONTO / SINGAPORE

Contents

PART I THE BACKGROUND TO PHARMACEUTICALS

- 1. History** **3**

- 2. The Characteristics of the Pharmaceutical Industry** **18**
 - 2.1 The World Pharmaceutical Industry / 18
 - 2.2 The Pharmaceutical Industry in the U.S. Economy / 22
 - 2.3 Profitability / 23
 - 2.4 Capital Investment / 24
 - 2.5 Research Expenditure / 25
 - 2.6 Employment / 28
 - 2.7 Patent Protection / 29
 - 2.8 Competition and Promotion / 30
 - 2.9 Manufacture of Products / 30
 - 2.10 Drug Testing / 32
 - 2.11 Drug Nomenclature and Generic Drugs / 36
 - 2.11.1 *Generic versus Branded Pharmaceuticals* / 38

- 3. Patterns of Illness and Health Care** **41**
 - 3.1 Ethical and Over-the-Counter Drugs / 41
 - 3.2 Physicians / 42
 - 3.3 Patients / 44
 - 3.3.1 *Mortality* / 44
 - 3.3.2 *Disability* / 48

- 3.3.3 *Visits to the Physician* / 50
- 3.3.4 *Prescribing Drugs* / 52
- 3.3.5 *Correlation* / 55

4. Pharmacological Concepts

56

- 4.1 Receptor Theory / 56
 - 4.1.1 *Enzymes* / 57
 - 4.1.2 *Nucleic Acids* / 58
 - 4.1.3 *Permeases* / 60
- 4.2 Radioligands / 61
 - 4.2.1 *Receptor Geometry* / 64
- 4.3 Replacements, Redesigned Agonists, and Antagonists / 65
 - 4.3.1 *Agonists* / 65
 - 4.3.2 *Antagonists* / 66
 - 4.3.3 *Drug Design* / 69
 - 4.3.4 *Structure–Activity Relations* / 70
- 4.4 What Happens to Drugs in the Body / 72
- 4.5 Drug Absorption and Dosage Forms / 74
 - 4.5.1 *Enteral Dosage* / 74
 - 4.5.2 *Percutaneous Dosage* / 76
 - 4.5.3 *Inhalation* / 77
 - 4.5.4 *Parenteral Dosage* / 78
 - 4.5.5 *Other Dosage Forms* / 79
- 4.6 Drug Distribution / 81
 - 4.6.1 *Binding to Plasma Protein and Blood Cells* / 81
 - 4.6.2 *Physical Properties of the Drug* / 82
 - 4.6.3 *Other Factors* / 82
- 4.7 Biotransformation of Drugs / 83
- 4.8 Excretion / 88
- 4.9 Bioavailability and the Digoxin Affair / 88
- 4.10 Properties of an Ideal Drug / 91
- 4.11 Conclusion / 93

PART II: THE TOP-100 DRUGS

5. The Production of Pharmaceuticals

97

- 5.1 The Top-100 Drugs / 97
- 5.2 Classification of Drugs / 101
- 5.3 Sources of Drugs / 104

5.4 Manufacturing Processes / 106

- 5.4.1 *Quality Control / 106*
- 5.4.2 *Choice of Reagents / 108*
- 5.4.3 *Plant Design / 108*
- 5.4.4 *Cost Structure / 109*

6. Antibacterials and Antibiotics**111**

- 6.1 **Classification of Bacteria / 113**
- 6.2 **Sulfonamides / 115**
- 6.3 **Penicillins / 120**
 - 6.3.1 *Penicillin Manufacture / 126*
 - 6.3.2 *Improving Penicillins / 128*
 - 6.3.3 *Semisynthetic Penicillins / 130*
 - 6.3.4 *Production of 6-Aminopenicillanic Acid / 132*
 - 6.3.5 *Production of Ampicillin and Amoxycillin / 133*
 - 6.3.6 *Penicillin Esters / 134*
 - 6.3.7 *β -Lactamase Inhibitors / 138*
 - 6.3.8 *The Future of Penicillins / 139*
- 6.4 **Cephalosporins / 142**
 - 6.4.1 *Manufacture of Cephalosporins / 145*
 - 6.4.2 *7-Oximinoacylcephalosporins / 148*
 - 6.4.3 *Cephameycin C Derivatives / 151*
 - 6.4.4 *Cephalosporins in Hospitals / 152*
- 6.5 **Tetracyclines / 152**
 - 6.5.1 *Manufacture of Tetracyclines / 154*
 - 6.5.2 *Rolitetraacycline / 156*
- 6.6 **Macrolide Antibiotics / 157**
- 6.7 **Aminoglycosides and Antituberculosis Drugs / 158**
 - 6.7.1 *Tuberculosis Therapy / 159*
- 6.8 **Peptide Antibiotics / 162**
- 6.9 **Quinolone Antibacterials / 163**
- 6.10 **Miscellaneous Antibacterials / 164**
 - 6.10.1 *Chloramphenicol and Nitrofurantoin / 164*
 - 6.10.2 *Lincomycin and Clindamycin / 167.*
 - 6.10.3 *Vancomycin / 168*
- 6.11 **Antifungals / 168**
- 6.12 **The Future / 170**

7. Cardiovascular Drugs**174**

- 7.1 **The Functioning of the Heart / 174**
 - 7.1.1 *Diseases of the Heart / 177*

- 7.2 Cardiac Glycosides / 179
- 7.3 Antiarrhythmics / 180
- 7.4 Diuretics / 182
 - 7.4.1 Carbonic Anhydrase Inhibitors / 184
 - 7.4.2 Low-Ceiling Diuretics / 184
 - 7.4.3 High-Ceiling (Loop) Diuretics / 187
 - 7.4.4 Potassium-Sparing Diuretics / 188
 - 7.4.5 Potassium Replenishers / 192
- 7.5 Coronary Vasodilators and β -Adrenergic Agents / 192
 - 7.5.1 Nitrates and Nitrites / 193
 - 7.5.2 Calcium Antagonists / 194
 - 7.5.3 Hemorheologic Agent / 196
 - 7.5.4 Mode of Action of β -Adrenergic Agents / 197
 - 7.5.5 β -Adrenergic Drugs / 200
 - 7.5.6 β -Adrenergic Blocking Drugs / 203
 - 7.5.7 α - and β -Adrenergic Drug / 207
- 7.6 Antihypertensive Agents / 207
 - 7.6.1 Centrally Acting Antihypertensives / 207
 - 7.6.2 Vasodilators / 211
 - 7.6.3 Adrenergic Neuron Blockers / 212
 - 7.6.4 Angiotensin-Converting Enzyme Inhibitors / 212
- 7.7 Anticoagulants / 214
- 7.8 Thrombolytic Agents / 218
- 7.9 Hypolipemics / 219
- 7.10 Conclusion / 222

8. Drugs Affecting the Central Nervous System

224

- 8.1 Hypnotics and Sedatives / 227
 - 8.1.1 Barbiturates / 227
 - 8.1.2 Nonbarbiturate Hypnotics and Sedatives / 229
 - 8.1.3 Anticonvulsants / 231
- 8.2 Major Tranquilizers (Neuroleptics) / 233
- 8.3 Anxiolytics (Minor Tranquilizers) / 238
 - 8.3.1 Benzodiazepines / 240
 - 8.3.2 Benzodiazepine Syntheses / 243
 - 8.3.3 Meprobamate, Hydroxyzine, and Buspirone / 248
 - 8.3.4 Benzodiazepine Antagonists and Mode of Action / 249
- 8.4 Antidepressants / 253
 - 8.4.1 Monoamine Oxidase Inhibitors / 253
 - 8.4.2 Tricyclic Antidepressants / 255
 - 8.4.3 Tetracyclic Antidepressants / 258
 - 8.4.4 Serotonin Reuptake Inhibitors / 261

8.5	Stimulants and Appetite Suppressants / 263	
8.5.1	<i>Amphetamine-like Anorectics</i> / 264	
8.5.2	<i>Caffeine and Cocaine</i> / 266	
8.6	Psychotomimetics / 268	
8.7	Use and Abuse / 270	
9.	Antihistamines	274
9.1	Allergy / 274	
9.2	Antiallergy and Antinausea Compounds / 276	
9.3	Nonsoporific Antihistamines / 279	
9.4	Syntheses of H ₁ Blockers / 280	
9.5	"Cold Cures" / 282	
9.6	H ₂ -Blocking Antihistamines and Antiulcer Drugs / 284	
9.6.1	<i>Syntheses of H₂ Blockers</i> / 289	
9.6.2	<i>Other Antiulcer Drugs</i> / 289	
10.	Analgesics	292
10.1	Narcotic Analgesics / 292	
10.1.1	<i>Antidiarrhea Drugs</i> / 294	
10.1.2	<i>Methadone and Propoxyphene</i> / 297	
10.1.3	<i>Morphine Antagonists</i> / 300	
10.1.4	<i>Opioid Receptors</i> / 301	
10.1.5	<i>Etorphine</i> / 301	
10.1.6	<i>Buprenorphine</i> / 303	
10.1.7	<i>Oxycodone, Hydrocodone, Dihydrocodeine, and Dextromethorphan</i> / 304	
10.2	Nonnarcotic Pain Relievers / 305	
10.2.1	<i>Aspirin</i> / 307	
10.2.2	<i>Acetaminophen (Paracetamol)</i> / 308	
10.3	Endorphins and Enkephalins / 310	
11.	Steroid Drugs	314
11.1	Natural Steroids / 314	
11.2	Conjugated Estrogenic Hormone / 317	
11.3	Oral Contraceptives / 318	
11.3.1	<i>Progesterone Antagonist</i> / 320	
11.3.2	<i>Risks of Oral Contraceptives</i> / 321	
11.4	Anti-inflammatory Steroids / 323	
11.5	Other Applications of Steroids / 325	
11.6	Manufacture of Steroids / 325	
11.6.1	<i>Steroids from Diosgenin</i> / 327	

11.6.2 Steroids from Stigmasterol / 328

11.6.3 Steroids from Sitosterol / 330

- 12. Nonsteroid Anti-inflammatory Agents** **334**
- 12.1 α -Arylpropionic Acids / 336
 - 12.1.1 Syntheses of Ibuprofen / 337
 - 12.1.2 Syntheses of Naproxen / 342
 - 12.1.3 Synthesis of Fenoprofen / 345
 - 12.2 Substituted Acetic Acid Derivatives / 346
 - 12.3 Enolic β -Diketones / 346
 - 12.4 Anthranilic/Salicylic Acid Derivatives / 350
 - 12.5 Other Anti-inflammatories / 350
 - 12.6 Conclusion / 351
- 13. Hypoglycemics** **353**
- 13.1 Replacement Therapy / 354
 - 13.2 Insulin via Recombinant DNA / 354
 - 13.3 Oral Hypoglycemics / 357
 - 13.3.1 Syntheses of Oral Hypoglycemics / 359
 - 13.4 Recent Developments / 361
- 14. Anticholinergic Drugs** **363**
- 14.1 The Solanaceous Alkaloids / 366
 - 14.2 Dicyclomine / 366
 - 14.3 Clidinium Bromide / 367
- 15. Antiasthma Drugs** **369**
- 15.1 β -Adrenergic Agonists / 370
 - 15.1.1 Syntheses of β_2 Agonists / 373
 - 15.2 Methylxanthine Bronchodilators / 375
 - 15.3 Disodium Cromoglycate / 377
 - 15.3.1 Dosage Forms / 378
 - 15.4 Steroids / 379
 - 15.5 Leukotriene Inhibitors / 379
- 16. Parkinson's Disease** **380**
- 16.1 Asymmetric Synthesis of Levodopa / 381
 - 16.2 Effects of Levodopa / 383
 - 16.3 Other Drugs / 384
 - 16.4 Huntingdon's Chorea / 385

17. Miscellaneous Drugs	387
17.1 Thyroid Hormones /	387
17.2 Muscle Relaxants /	389
17.3 Allopurinol /	390
17.4 Antismoking Drug /	391
17.5 Acne Treatment /	391
17.6 Metoclopramide /	392
17.7 Vitamins /	393
17.7.1 Vitamin C /	393
17.7.2 Vitamin A /	396
17.7.3 Vitamin B ₁₂ /	397

PART III DRUG GROUPS OUTSIDE THE TOP-100

18. Tropical Diseases	401
18.1 Insecticides /	403
18.2 Antiprotozoals /	404
18.2.1 Malaria /	404
18.2.2 Trypanosomiasis and Leishmaniasis /	410
18.2.3 Amebiasis and Trichomoniasis /	411
18.3 Helminth Infections /	413
18.3.1 Drugs against Nematodes /	414
18.3.2 Drugs against Trematodes /	416
18.4 Tuberculosis, Cholera, Typhoid Fever, Leprosy /	418
18.5 Yellow Fever and Hepatitis /	420
18.6 Conclusion /	421
19. Prostaglandins	422
19.1 The Arachidonic Acid Cascade /	423
19.1.1 Prostaglandin Endoperoxides and Prostaglandins /	426
19.1.2 Thromboxanes /	429
19.1.3 Prostacyclin /	430
19.1.4 Leukotrienes /	431
19.2 Prostaglandin Syntheses /	434
19.3 Novel Nonnarcotic Analgesics /	434
19.4 Steroids and Prostaglandins /	436

20. Antiviral Drugs	438
20.1 Replication of Viruses / 439	
20.2 Virus Infections / 441	
20.3 Pyrimidine and Purine Antimetabolites / 442	
20.4 Amantadine / 444	
20.5 Drugs against AIDS / 445	
20.6 Other Antiviral Drugs / 446	
21. Anticancer Drugs	448
21.1 Origins of Cancer / 448	
21.2 Prevention and Treatment / 451	
21.3 Steroids / 452	
21.4 Alkylating Agents / 453	
21.5 Antimetabolites / 454	
21.6 Antibiotics / 456	
21.7 Platinum Complexes / 457	
21.8 Miscellaneous Drugs / 458	
22. Orphan Drugs	460
23. Innovations and Issues	463
23.1 New Chemical Entities 1986–1988 / 463	
23.2 The Achievement of the Pharmaceutical Industry / 467	
23.3 The Problems of the Pharmaceutical Industry / 468	
23.3.1 <i>Adverse Drug Reactions</i> / 468	
23.3.2 <i>Overprescribing</i> / 469	
23.3.3 <i>Are Profits Excessive?</i> / 469	
23.4 Drugs of the Future / 471	
23.5 Conclusion / 472	
Appendixes	
1. The Most Widely Prescribed Drugs by Chemical Entity / 475	
2. International Classification of Diseases / 478	
3. Bibliography and Notes / 482	
Index	499